Group 1 - The stock price of TianKang as of August 12, 2025, closed at 35.98 yuan, down 0.96% from the previous trading day, with a trading volume of 63,031 hands and a transaction amount of 226 million yuan [1] - TianKang's main business includes the research, production, and sales of pharmaceutical products. The company recently hosted a summit on innovative immunotherapy clinical transformation research, focusing on cutting-edge developments in the field of immunotherapy [1] - Chairman Zheng Hanjie stated at the summit that China's innovative drug industry is transitioning from "catching up" to "running alongside" and even "leading" [1] Group 2 - On the evening of August 12, the company announced a change in its continuous supervision sponsor representative, with Wang Ning replacing Liu Xiangmao to continue the supervision work [1] - The global pioneering small molecule drug CKBA, which the company is involved in developing, received attention at the summit. This drug targets the treatment of skin diseases such as vitiligo [1]